Proof-of-concept for ChronSeal®
ChronTech now can report that one week after completed one-week’s treatment with ChronSeal® the healing was significantly better for the two groups receiving active substance as compared to placebo (mean for reduction of wound sizes was 34% and 30%, respectively as compared to -6% for placebo). This gives proof-of-concept for ChronSeal® as treatment of chronic leg wounds.
In the now completed multi-center study conducted in Sweden and Norway ChronTech has received proof-of-concept for ChronSeal® as a therapy for the treatment of chronic leg wounds. In the study two dose groups were compared to placebo. The patients were treated for one week and thereafter followed for another 11 weeks. No drug related serious adverse events were reported. One week after treatment the healing was significantly better in the two groups who had received active substance, i.e. hepatocyte growth factor (HGF), as compared to the placebo group. This gives proof-of-concept for ChronSeal® as treatment of chronic leg wounds. At follow up no appreciable further healing were observed in the two treatment groups. Studies are now being planned for finding the optimal dose and treatment duration for obtaining the best treatment results.
”It is with satisfaction we can establish that our candidate drug works in man. An intensive work lies ahead of us in the clinical development. It is with excitement we look forward to initiate the clinical studies that will take us closer to a final therapeutic drug” says Anders Vahlne, ChronTech Pharma’s CEO.
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se
About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.